Dermatologists are moving beyond traditional topical treatments to address some of the most stubborn chronic skin conditions, with new real-world evidence showing that targeted biologic medications can dramatically improve patients' lives. At the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, pharmaceutical company LEO Pharma will present 17 scientific studies highlighting breakthrough data on three conditions that have historically been difficult to treat: atopic dermatitis (AD), chronic hand eczema (CHE), and generalized pustular psoriasis (GPP). These presentations mark a significant shift in how dermatologists approach inflammatory skin diseases. Rather than focusing solely on symptom management, the new research emphasizes real-world patient outcomes, long-term safety, and quality of life improvements. For millions of people living with these conditions, the findings could mean better treatment options and a clearer path to clearer skin. What Are These Chronic Skin Conditions, and Why Are They So Hard to Treat? Atopic dermatitis is a chronic inflammatory skin disease characterized by intense itching and eczematous lesions. It results from a combination of skin barrier dysfunction and immune system dysregulation, leading to persistent inflammation. The condition affects people of all ages and can significantly impact daily life, sleep, and mental health. Chronic hand eczema presents a unique challenge because hands are constantly exposed to irritants, water, and environmental stressors. This makes the condition particularly difficult to manage with standard creams alone. Generalized pustular psoriasis is even more serious; it's a rare but potentially life-threatening condition with mortality rates ranging from 2% to 16% due to severe complications like multisystem organ failure and sepsis. Many GPP patients also suffer from various comorbidities, compounding the burden on both patients and healthcare systems. What New Data Will Dermatologists Be Discussing at AAD 2026? LEO Pharma's research portfolio spans three major medication categories, each targeting different aspects of inflammatory skin disease: - ADBRY (tralokinumab) for Atopic Dermatitis: The company will present 12-month real-world data from the TRACE study, including analyses of patients with hand and foot involvement and patients with skin of color, demonstrating minimal disease activity and sustained effectiveness. - ANZUPGO (delgocitinib) for Chronic Hand Eczema: New data will evaluate outcomes in adults with moderate-to-severe CHE, including results for patients with and without prior systemic therapy exposure, further characterizing treatment response in this difficult-to-treat population. - SPEVIGO (spesolimab) for Generalized Pustular Psoriasis: Long-term data from the EFFISAYIL program will evaluate both intravenous and subcutaneous treatment options for GPP flares and characterize the baseline non-flaring disease phenotype. The significance of these presentations lies in their focus on real-world evidence rather than controlled clinical trial data alone. Real-world studies track how medications perform in everyday clinical practice, across diverse patient populations, and over extended periods. This approach provides dermatologists with practical insights into which treatments work best for specific patient subgroups. "We're proud to present LEO Pharma's largest body of research to date at the AAD Annual Meeting, highlighting new real-world and clinical insights across Atopic Dermatitis, Generalized Pustular Psoriasis and Chronic Hand Eczema," said Sophie Lamle, EVP, Development at LEO Pharma. "Together, these findings reflect continued advancements in the understanding and management of chronic dermatologic diseases and underscore our ambition to help address critical treatment gaps for patients." Sophie Lamle, EVP, Development at LEO Pharma How Do These New Treatments Work Differently Than Traditional Approaches? Traditional treatments for inflammatory skin conditions often rely on topical corticosteroids or emollients, which can lose effectiveness over time or cause side effects with prolonged use. The new medications represent a paradigm shift by targeting specific immune pathways that drive inflammation. Atopic dermatitis, for example, is driven by excessive production of type 2 cytokines, including IL-13, and IL-22, which contribute to the pathophysiology of the disease. Tralokinumab specifically targets IL-13, addressing one of the root causes of inflammation rather than just treating symptoms. Similarly, spesolimab targets the IL-36 pathway, which is a key driver of generalized pustular psoriasis. By interrupting these specific immune signals, these medications can achieve more sustained disease control and allow patients to experience periods of minimal disease activity. Why Should Patients Care About Real-World Evidence? Clinical trials are conducted under carefully controlled conditions with specific patient populations. Real-world evidence, by contrast, captures how treatments perform in actual medical practice across diverse groups of patients with varying ages, skin types, disease severity, and comorbidities. The TRACE study, for instance, specifically examined treatment effectiveness in patients with skin of color, a population historically underrepresented in dermatological research. This inclusive approach ensures that the data reflects outcomes for a broader range of patients. Additionally, real-world studies track long-term outcomes over extended periods. The 12-month data from the TRACE study and the multi-year data from the EFFISAYIL program provide dermatologists with confidence that improvements in skin clearance and disease control are sustained, not just temporary. For patients, this means knowing that a treatment recommended by their dermatologist has been proven to work over the long haul, not just in a six-week clinical trial. How to Discuss These Treatment Options With Your Dermatologist If you're living with atopic dermatitis, chronic hand eczema, or another inflammatory skin condition, understanding the latest treatment landscape can help you have more informed conversations with your dermatologist: - Ask About Biologic Options: If topical treatments alone haven't provided adequate relief, ask your dermatologist whether you might be a candidate for biologic medications that target specific immune pathways underlying your condition. - Discuss Real-World Outcomes: Request information about how treatments perform in real-world settings, not just clinical trials. Ask about long-term safety data and whether the medication has been studied in patient populations similar to yours. - Explore Quality of Life Improvements: Beyond skin clearance, ask your dermatologist about the impact of treatment on sleep, itch relief, and overall quality of life. These outcomes matter as much as clinical measures. - Understand Your Skin Type Representation: If you have skin of color, ask whether the treatment you're considering has been studied in diverse populations to ensure the data applies to you. The presentations at AAD 2026 represent a turning point in dermatology. By emphasizing real-world evidence, long-term outcomes, and patient experience, dermatologists are gaining a clearer picture of how to match the right treatment to the right patient. For people struggling with chronic inflammatory skin diseases, this means hope for better outcomes and a higher quality of life.
